Caspofungin acetate-loaded glyceryl monostearate lipid nanoparticles, preparation method thereof, and application thereof in antifungal infection
By encapsulating caspofungin acetate in glyceryl monostearate, the problem of poor hepatotoxicity and solubility of high doses of antifungal drugs is solved, and the dose reduction, enhance antibacterial effect and reduce side effects are achieved. The goal of the treatment of Candida albicans has significantly improved the effect of treatment.
Patent Information
- Application Number
- CN202410194046.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-02-21
AI Technical Summary
Existing antifungal drugs such as caspofungin acetate have hepatotoxic side effects when used at high doses, and their high cost and poor solubility lead to limited synergistic antibacterial efficacy in the body, making it difficult to effectively reduce the dose used and maintain the efficacy.
Using glyceryl monostearate monostearate lipid nanoparticles loaded with caspofungin acetate, solid lipid nanoparticles are formed by encapsulating caspofungin acetate in solid glyceryl monostearate to improve drug stability and biological Compatibility and prepared by a combination of sonication and emulsifiers to enhance its antibacterial effect on Candida albicans.
It significantly reduced the dose of caspofungin acetate, enhanced its antibacterial effect on Candida albicans, reduced the cost of medication in patients, and avoided the toxic side effects during high dose use, significantly prolonged the survival cycle of mice. and reduce the kidney bacteria loading.
Smart Images

Figure CN118021763B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of fungal infection, and in particular to glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, a preparation method thereof, and application thereof in antifungal infection. Background Art
[0002] Antifungal infection, especially deep fungal infection, is an important research topic in antimicrobial infection. In recent years, the incidence and mortality of fungal infection have increased year by year in immunocompromised and intensive care patients, and the mortality rate of invasive Candida infection has reached about 40%. Candida albicans is the most common pathogen in fungal infection and can colonize in the skin, mouth, intestines and other parts of the normal human body. Clinically, polyenes, echinocandins, azoles and allylamines are the most commonly used drugs for the treatment of fungal infections. However, due to the widespread occurrence of fungal resistance and the formation of biofilms, it is difficult to discover new active molecules, and the application of antifungal drugs faces new challenges. Therefore, increasing the efficacy of antifungal drugs and reducing toxic side effects are important directions for the research and development of antifungal drugs.
[0003] Caspofungin acetate (CAS) is a semisynthetic antifungal drug of the echinocandin class. It acts on the cell wall of fungal cells and can effectively inhibit the biosynthesis of β-1,3-D-glucan in the cell wall. It is currently the first-line drug for the treatment of systemic Candida albicans infection. However, CAS is expensive, and fluconazole is used as a maintenance treatment after one cycle (two weeks) of conventional clinical doses. At the same time, studies have shown that 65% of patients in the high-dose group will experience liver toxicity, including elevated liver enzymes and liver failure, when receiving CAS at three times the approved dose. Therefore, reducing its dosage while maintaining the original efficacy can significantly reduce the patient's medication costs and avoid toxic side effects when used at high doses. In previous studies, our research group found that the combination of stearic acid monoglyceride (GMS) and CAS has a good synergistic effect, enhancing the in vitro antibacterial effect of CAS. The in vitro antibacterial MIC of the combination of the two was reduced from 0.25μg / mL to 0.0313μg / mL (Study on the in vitro anti-Candida activity of stearic acid monoglyceride synergistic with caspofungin. Chinese Journal of Mycology, 2021, 6(3): 145-149). However, the solubility of GMS and CAS is very different, and how to administer the drug will affect the synergistic antibacterial effect of the two components on the fungal infection site in vivo.
[0004] In view of this, the present inventors studied and designed a glyceryl monostearate lipid nanoparticle loaded with caspofungin acetate, a preparation method thereof, and an application thereof in antifungal infection, and thus the present case was generated. Summary of the invention
[0005] The object of the present invention is to provide a glyceryl monostearate lipid nanoparticle loaded with caspofungin acetate, which reduces the dosage of caspofungin acetate while maintaining the original therapeutic effect, reduces the medication cost for patients, and avoids toxic side effects when used in high doses.
[0006] In order to achieve the above object, the technical solution adopted by the present invention to solve the technical problem is:
[0007] A glyceryl monostearate lipid nanoparticle loaded with caspofungin acetate comprises the following raw materials in parts by weight: 0.5-2 parts of caspofungin acetate, 15-25 parts of glyceryl monostearate, 4-6 parts of a first emulsifier, 1-3 parts of a co-emulsifier, 1-3 parts of a second emulsifier and 1000-3000 parts of water.
[0008] Preferably, the first emulsifier is lecithin.
[0009] Preferably, the co-emulsifier is one or more of methanol, ethanol, propylene glycol and n-butanol.
[0010] Preferably, the second emulsifier is one or more of Tween series, Span series, and Poloxamer series.
[0011] Preferably, the lipid nanoparticles include the following raw materials in parts by weight: 1 part of caspofungin acetate, 20 parts of glyceryl monostearate, 5 parts of lecithin as a first emulsifier, 1 part of methanol as a co-emulsifier, 2 parts of poloxamer-188 as a second emulsifier, and 1000 parts of water.
[0012] The present invention also provides a method for preparing glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, comprising the following steps:
[0013] S1, mixing the caspofungin acetate, the glyceryl monostearate, the first emulsifier and the co-emulsifier to prepare an oil phase;
[0014] S2, mixing the second emulsifier and water to obtain an aqueous phase;
[0015] S3, mixing the oil phase and the water phase to obtain colostrum; subjecting the colostrum to ultrasound, wherein the ultrasound conditions are power 200-300 W, ultrasound 0.5-2 s, interval 0.5-2 s; total time 8-15 min; refrigerating and solidifying overnight to obtain monostearate glyceryl lipid nanoparticles loaded with caspofungin acetate.
[0016] Preferably, in S1, the first emulsifier and the auxiliary emulsifier are mixed by magnetic stirring at a temperature of 50-70°C.
[0017] Preferably, in S2, after the second emulsifier and water are mixed, the water phase is heated to 50-70°C.
[0018] Preferably, in S3, the aqueous phase is slowly dripped into the oil phase under magnetic stirring conditions, and stirring is continued under heating conditions to obtain the colostrum.
[0019] Preferably, in S3, after obtaining the colostrum, the ultrasonic conditions are as follows: power 250 W, ultrasound 1 s, interval 1 s; the total time is 10 min.
[0020] The present invention also provides an application of glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, which is used to enhance the antibacterial effect of caspofungin acetate on Candida albicans.
[0021] The present invention uses glyceryl monostearate as a matrix to encapsulate caspofungin acetate, and prepares a solid lipid nanoparticle for synergistic resistance to Candida albicans infection. The lipid nanoparticles (Solid lipidnanoparticles, SLNs) of the present invention use solid glyceryl monostearate GMS as a carrier, and the caspofungin acetate drug is wrapped or embedded in the carrier to form a nano drug delivery system, which improves the stability of the drug, and has the characteristics of low toxicity, good biocompatibility, good physical stability, and the drug is not easy to leak in the systemic circulation. The caspofungin acetate solid lipid nanoparticles prepared by the present invention using glyceryl monostearate GMS as a carrier material have a synergistic effect on the antibacterial effect of caspofungin acetate, and enhance the antifungal effect of caspofungin acetate in vivo and in vitro. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The particle size (A), Zeta potential (B) and transmission electron microscopy (C) images of CAS-SLNs of the embodiments of the present invention;
[0023] Figure 2 The MIC value of CAS-SLNs against Candida albicans of the present invention is measured;
[0024] Figure 3 The inhibitory effect of CAS-SLNs of the present invention on Candida albicans biofilm (n=3);
[0025] Figure 4 Crystal violet staining was used to observe the effect of CAS-SLNs of the present invention on Candida albicans biofilm;
[0026] Figure 5 Survival curve analysis of mice with deep Candida albicans infection treated with CAS-SLNs according to the present invention (n=8);
[0027] Figure 6 The effect of CAS-SLNs of the present invention on the bacterial load in the kidneys of mice with deep Candida albicans infection;
[0028] Figure 7 This is a PAS staining image of the kidney of mice deeply infected with Candida albicans treated with CAS-SLNs according to an embodiment of the present invention. DETAILED DESCRIPTION
[0029] like Figure 1 As shown, the present invention discloses a glyceryl monostearate lipid nanoparticle loaded with caspofungin acetate, comprising the following raw materials in parts by weight: 0.5-2 parts of caspofungin acetate, 15-25 parts of glyceryl monostearate, 4-6 parts of a first emulsifier, 1-3 parts of a co-emulsifier, 1-3 parts of a second emulsifier and 1000-3000 parts of water.
[0030] Preferably, the first emulsifier is lecithin.
[0031] Preferably, the co-emulsifier is one or more of methanol, ethanol, propylene glycol and n-butanol.
[0032] Preferably, the second emulsifier is one or more of Tween series, Span series, and Poloxamer series.
[0033] Preferably, the lipid nanoparticles include the following raw materials in parts by weight: 1 part of caspofungin acetate, 20 parts of glyceryl monostearate, 5 parts of lecithin as a first emulsifier, 1 part of methanol as a co-emulsifier, 2 parts of poloxamer-188 as a second emulsifier, and 1000 parts of water.
[0034] The present invention also provides a method for preparing glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, comprising the following steps:
[0035] S1, mixing the caspofungin acetate, the glyceryl monostearate, the first emulsifier and the co-emulsifier to prepare an oil phase;
[0036] S2, mixing the second emulsifier and water to obtain an aqueous phase;
[0037] S3, mixing the oil phase and the water phase to obtain colostrum; subjecting the colostrum to ultrasound, wherein the ultrasound conditions are power 200-300 W, ultrasound 0.5-2 s, interval 0.5-2 s; total time 8-15 min; refrigerating and solidifying overnight to obtain monostearate glyceryl lipid nanoparticles loaded with caspofungin acetate.
[0038] Preferably, in S1, the first emulsifier and the auxiliary emulsifier are mixed by magnetic stirring at a temperature of 50-70°C.
[0039] Preferably, in S2, after the second emulsifier and water are mixed, the water phase is heated to 50-70°C.
[0040] Preferably, in S3, the aqueous phase is slowly dripped into the oil phase under magnetic stirring conditions, and stirring is continued under heating conditions to obtain the colostrum.
[0041] Preferably, in S3, after obtaining the colostrum, the ultrasonic conditions are as follows: power 250 W, ultrasound 1 s, interval 1 s; the total time is 10 min.
[0042] Example 1
[0043] A caspofungin acetate-loaded glyceryl monostearate lipid nanoparticle comprises the following raw materials in parts by weight: 0.5 parts of caspofungin acetate, 25 parts of glyceryl monostearate, 4 parts of lecithin, 1 part of propylene glycol, 1 part of Tween 80 and 2000 parts of water.
[0044] The preparation method of the above embodiment is:
[0045] S1. Weigh the above-mentioned caspofungin acetate, glyceryl monostearate, lecithin and propylene glycol in parts by weight, and mix them under magnetic stirring at a temperature of 50° C. to prepare an oil phase;
[0046] S2, mixing the above-mentioned parts by weight of Tween 80 and water to prepare an aqueous phase, and heating the aqueous phase to 50° C.;
[0047] S3. Under magnetic stirring conditions, slowly dripping the aqueous phase into the oil phase, and continuously stirring under heating conditions to obtain the colostrum; subjecting the colostrum to ultrasound, the ultrasound conditions are as follows: power 200 W, ultrasound 2 seconds, interval 2 seconds; total time is 15 minutes; refrigerating and solidifying at 4°C overnight to obtain monostearate glyceryl lipid nanoparticles loaded with caspofungin acetate, i.e., CAS-SLNs.
[0048] Example 2
[0049] The invention discloses glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, comprising the following raw materials in parts by weight: 1 part of caspofungin acetate, 20 parts of glyceryl monostearate, 5 parts of lecithin, 1 part of methanol, 2 parts of poloxamer-188 and 1000 parts of water.
[0050] The preparation method of the above embodiment is:
[0051] S1. Weigh the above-mentioned caspofungin acetate, glyceryl monostearate, lecithin and methanol in parts by weight, and mix them under magnetic stirring at 60° C. to prepare an oil phase;
[0052] S2, mixing the above-mentioned parts by weight of poloxamer-188 and water to obtain an aqueous phase, and heating the aqueous phase to 60° C.;
[0053] S3. Under magnetic stirring conditions, slowly dripping the aqueous phase into the oil phase, and continuously stirring under heating conditions to obtain the colostrum; subjecting the colostrum to ultrasound, the ultrasound conditions are power 250 W, ultrasound 1 s, interval 1 s; the total time is 10 min; refrigerating and solidifying at 4°C overnight to obtain glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, i.e., CAS-SLNs.
[0054] Example 3
[0055] The invention discloses glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, comprising the following raw materials in parts by weight: 2 parts of caspofungin acetate, 15 parts of glyceryl monostearate, 6 parts of lecithin, 3 parts of ethanol, 3 parts of poloxamer-407 and 3000 parts of water.
[0056] The preparation method of the above embodiment is:
[0057] S1. Weigh the above-mentioned caspofungin acetate, glyceryl monostearate, lecithin and ethanol in parts by weight, and mix them under magnetic stirring at 70° C. to prepare an oil phase;
[0058] S2, mixing the above-mentioned parts by weight of Poloxamer-407 and water to obtain an aqueous phase, and heating the aqueous phase to 70° C.;
[0059] S3. Under magnetic stirring conditions, slowly dripping the aqueous phase into the oil phase, and continuously stirring under heating conditions to obtain the colostrum; subjecting the colostrum to ultrasound, the ultrasound conditions are as follows: power 300 W, ultrasound 0.5 s, interval 0.5 s; total time 8 min; refrigerating and solidifying at 4°C overnight to obtain glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate, i.e., CAS-SLNs.
[0060] The present invention conducted the following experiment using the caspofungin acetate-loaded glyceryl monostearate lipid nanoparticles prepared in Example 2 above:
[0061] 1. The particle size and Zeta potential of SLNs were measured by dynamic light scattering, and the surface morphology was observed by transmission electron microscopy. The particle size and Zeta potential of CAS-SLNs were 135.97±1.73nm and 19.33±0.37mV, respectively. Figure 1 As shown in the figure, transmission electron microscopy pictures show that CAS-SLNs are quasi-round particles with a particle size of about 130 nm. The nanoparticle encapsulation efficiency is 67.71±1.74% and the drug loading is 7.55±0.68%.
[0062] 2. Determination of CAS content. CAS was determined by HPLC. Chromatographic column: Diamonsil Plus C18 chromatographic column (4.6×250mm, 5μm); mobile phase: acetonitrile: 0.1% phosphoric acid (35:65); flow rate: 1mL / min; detection wavelength: 227nm; column temperature: 25℃; injection volume: 20μL. Specificity investigation: Take the standard solution of caspofungin acetate, blank SLNs solution, and CAS-SLNs solution, filter them through a 0.22μm filter membrane, and then determine them by HPLC. Linearity and range: Accurately weigh the solutions of CAS configuration series with concentrations of 1, 5, 10, 20, 40, and 50μg / mL. Draw a standard curve with CAS concentration versus peak area. The retention time of CAS is 6.8min, and the blank SLNs carrier has no interference with the determination of CAS-SLNs. Take low, medium, and high concentrations within 1 day and for 3 consecutive days to determine the concentration and calculate the RSD. The results show that the RSD values of intra-day precision and inter-day precision are less than 5%, and the precision of the established method meets the requirements. Stability determination, the RSD of the same sample at 0, 1, 2, 3, 5, 8, 12, 24h is 1.88%, indicating that the stability of the content determination meets the requirements. The recovery rate of the sample at low, medium and high concentrations is 95% to 115%, and the RSD values are all less than 5%, indicating that the method is stable and reliable and can be used to determine the CAS content in the sample.
[0063] 3. Determination of minimum inhibitory concentration (MIC) of CAS-SLNs
[0064] The test strain Candida albicans was inoculated on an SDA plate and activated twice in advance, cultured at 30°C for 48 h, and single clones of uniform size were selected and dissolved in YPD medium. The culture was cultured in a shaking incubator for 12 h to prepare a bacterial solution. After washing with PBS, the bacterial solution was resuspended in RPMI 1640 and adjusted to 1×10 3 ~5×10 3 CFU / mL.
[0065] Take a 96-well plate and add 100 μL RPMI 1640 medium as a blank control. 100 μL bacterial solution was used as a positive control. After adding 100 μL bacterial solution to the experimental group, different sample groups were added for incubation. The groups were divided into: CAS, CAS+GMS (CAS and GMS physical mixture), CAS+SLNs (CAS and blank SLNs physical mixture), CAS-SLNs. Serial dilution was performed to make the CAS concentration 3.13×10 -2 μg / mL, 1.57×10 -2 μg / mL, 7.83×10 -3 μg / mL, 3.91×10 -3 μg / mL, 1.96×10 -3 μg / mL, 9.78×10 -4μg / mL, 4.89×10 -4 μg / mL, 2.45×10 -4 μg / mL, 1.23×10 -4 μg / mL, 6.13×10 -5 μg / mL, 3.06×10 -5 μg / mL. Incubate at 30℃ for 24h, and measure the OD value at λ=630nm using a microplate reader. MIC is defined as the OD value of Candida albicans. 630 Reduces minimum drug concentration by more than 80%.
[0066] The results are as follows Figure 2 As shown in the figure, after combined use with 1 μg / mL GMS, the MIC of the CAS group increased from 3.13×10 -2 μg / mL decreased to 7.83×10 -3 μg / mL, the sensitivity of Candida albicans to CAS increased by 4 times, indicating that CAS can synergize with GMS to inhibit the growth of Candida albicans. The MIC of the CAS-SLNs group was 9.78×10 -4 μg / mL, which was 32 times more active than that of CAS alone, indicating that CAS-SLNs could exert the synergistic effect of CAS and GMS to inhibit the growth of Candida albicans, and its antibacterial activity was significantly better than that of the physical mixture of CAS and GMS (P<0.001).
[0067] 4. CAS-SLNs inhibit biofilm
[0068] The biofilm formed by the mixture of hyphae and yeast is an important factor in the drug resistance of Candida albicans. Crystal violet staining was used to quantitatively detect the inhibitory effect of CAS-SLNs on the biofilm formation of Candida albicans.
[0069] Preparation of biofilm plates: 1640 medium was used to adjust the concentration of Candida albicans to 3 × 10 6 CFU / mL. Take a 96-well plate, add 100μL RPMI1640 medium to the first column as a blank control; add 100μL bacterial solution to the second to 12 columns and culture at 37℃. After the biofilm was incubated with the template for 90min, the supernatant was discarded and washed with PBS. Prepare the drug sensitivity plate: grouped as CAS, CAS+GMS, CAS+SLNs, CAS-SLNs, the CAS concentration in the nanoparticles or free drugs was 0.313μg / mL as the initial concentration, and diluted in multiples. Add the drug sensitivity plate to the biofilm plate and incubate at 37℃ for 24h. After washing the biofilm with PBS, add 0.4% crystal violet to stain, rinse with PBS, add alcohol to decolorize, take the supernatant, and measure the OD value at λ=630nm with an enzyme reader (n=3). At the same time, observe the film formation under a microscope.
[0070] The results are as follows Figure 3CAS group was 4.89×10 -4 mg / mL, 9.78×10 -4 mg / mL, 1.96×10 -3 The inhibition rates of capsule formation at the concentrations of 1.96×10-1 mg / mL were 30.70±8.96%, 36.50±5.78%, and 37.30±4.40%, respectively. At the same concentrations, the inhibition rates of capsule formation in the CAS-SLNs group were 56.12±2.83%, 68.05±7.72%, and 85.03±1.59%, respectively. At the same CAS concentration, the inhibition rates of the CAS-SLNs group were 1.8, 1.8, and 2.2 times that of the CAS group, and the inhibition rate of the CAS-SLNs group was significantly better than that of the CAS group (P<0.001). At a lower drug concentration of 1.96×10-1 mg / mL, the CAS-SLNs group -3 mg / mL compared with the high concentration of CAS group (1.57×10 -2 mg / mL) had the same biofilm inhibition effect (P>0.05), indicating that GMS significantly increased the antibacterial effect of CAS. Figure 4 It shows that when the concentration is 2.45×10 -4 When the concentration of CAS-SLNs was 2.1747mg / mL, the biofilm of Candida albicans in the CAS-SLNs group was significantly inhibited, and the inhibitory effect of CAS-SLNs on biofilm formation was significantly enhanced compared with CAS alone.
[0071] 5. Survival curve analysis of mice with deep Candida albicans infection treated with CAS-SLNs
[0072] ICR mice, female, 6-8 weeks old, were injected with SC5314 Candida albicans via tail vein. The injection dose was 1×10 5 CFU / mouse. The mice were killed after 1 day, and the kidney tissue sections were collected for PAS staining. After the experimental animals were modeled, they were divided into the following groups: Control group (normal saline), CAS group, and CAS-SLNs group, with 8 mice in each group. Tail vein injection, 200μL / mouse (CAS 0.2mg / kg), was given at intervals of 24h for 3 consecutive times. After administration, the mice were observed for 20 consecutive days, the weight of the mice was recorded every day, and the survival rate was calculated. The results are shown in Figure 5 As shown in the figure, mice in the control group began to die on the 6th day, and all died on the 10th day. The survival period of mice in the experimental groups was prolonged to varying degrees. After 20 days, the survival rates of the CAS group and the CAS-SLNs group were 40% and 70%, respectively. Compared with the CAS free drug group and the control group, the CAS-SLNs group could effectively prolong the survival time of infected mice (P<0.001). CAS-SLNs had a more significant inhibitory effect on deep fungal infection at the same concentration.
[0073] 6. Effect of CAS-SLNs on the bacterial load in the kidneys of mice with deep Candida albicans infection
[0074] ICR mice, female, 6-8 weeks old, were injected with SC5314 Candida albicans via tail vein. The injection dose was 1×10 5 CFU / mouse. The mice were killed after 1 day, and the kidney tissue sections were collected for PAS staining. The experimental animals were divided into Control group, CAS group, and CAS-SLNs group, with 8 animals in each group. After modeling and grouping, normal saline, CAS, and CAS-SLNs were injected into the tail vein at 200μL / mouse (CAS 0.2mg / kg), respectively. The drugs were given once 2h after modeling was completed and once after 24h, for a total of two doses. The animals were killed 48h after modeling, and the kidney tissue was taken, weighed, and placed in PBS to grind into a homogenate. The tissue homogenate was diluted and inoculated on the SDA plate. The colonies were counted after culturing at 30℃ for 48h. Figure 6 As shown, the bacterial loads in the Control group, CAS group, and CAS-SLNs group were 5.84±0.05 CFU / g, 5.18±0.03 CFU / g, and 5.10±0.06 CFU / g, respectively. There were significant differences in kidney bacterial loads between each experimental group and the Control group (P<0.001), and the bacterial load in the CAS-SLNs group was lower than that in the CAS group (P<0.05).
[0075] The mice were killed 48 hours after infection, and their kidney tissues were taken and stained with periodic acid-Schiff reagent (PAS) to investigate the infection of Candida albicans in the mouse kidneys. 48 hours after SC5314 Candida albicans infection in mice, a large number of Candida albicans were found in the renal pathological sections stained with PAS. The number of Candida albicans in the kidneys of the CAS group decreased significantly. However, Candida albicans was rarely found in the kidney sections of mice in the CAS-SLNs group with the same dose. Figure 7 This indicates that CAS-SLNs significantly reduced the bacterial load in the kidneys compared with CAS alone.
[0076] The present invention studies the therapeutic effect of glyceryl monostearate (GMS) solid lipid nanoparticles loaded with caspofungin acetate (CAS) on Candida albicans infection. On the one hand, GMS is used as a skeleton material to encapsulate caspofungin acetate to form drug-loaded nanoparticles in an aqueous solution system, which solves the problem that glyceryl monostearate is fat-soluble and needs to be dissolved in an organic solvent for administration. At the same time, GMS also has an antifungal synergistic effect. The MIC of CAS-SLNs is 3.13×10- -2 μg / mL and 7.83×10 -3 μg / mL decreased to 9.78×10 -4μg / mL, significantly increasing the inhibitory effect of caspofungin on Candida albicans. As the carrier matrix degrades, the drug in the nanoparticles is gradually released, and forms a synergistic antibacterial environment with the GMS in the carrier locally for a long time, thereby increasing the antibacterial activity of the drug. The present invention provides a new idea for the subsequent dosage form modification of caspofungin, which can solve the problem of high cost of clinical caspofungin drug treatment.
[0077] The above description is only a preferred embodiment of the present invention, and therefore cannot be used to limit the scope of the present invention. That is, equivalent changes and modifications made according to the patent scope of the present invention and the contents of the specification should still fall within the scope of the present invention.
Claims
1. A glyceryl monostearate lipid nanoparticle loaded with caspofungin acetate, Features: The invention comprises the following raw materials in parts by weight: 1 part of caspofungin acetate, 20 parts of glyceryl monostearate, 5 parts of lecithin, 1 part of methanol, 2 parts of poloxamer-188 and 1000 parts of water; The method for preparing lipid nanoparticles is characterized by comprising the following steps: S1, mixing the caspofungin acetate, the glyceryl monostearate, the lecithin and the methanol to prepare an oil phase; the lecithin and the methanol are mixed by magnetic stirring at a temperature of 60° C.; S2, mixing the poloxamer-188 and water to obtain an aqueous phase; after the poloxamer-188 and water are mixed, the aqueous phase is heated to 60° C.; S3. Under magnetic stirring conditions, slowly drip the aqueous phase into the oil phase, and continue stirring under heating conditions to obtain colostrum; subject the colostrum to ultrasound, and the ultrasound conditions are power 250 W, ultrasound 1 s, interval 1 s; the total time is 10 min; refrigerate and solidify overnight to obtain monostearate glyceryl lipid nanoparticles loaded with caspofungin acetate.
2. Use of the glyceryl monostearate lipid nanoparticles loaded with caspofungin acetate as claimed in claim 1 in the preparation of a drug for enhancing the inhibition of Candida albicans.
Citation Information
Patent Citations
Preparation method of lipid nanoparticles
CN102048696A
Caspofungin acetate pharmaceutical composition for injection and preparation method thereof
CN109758426A
Novel encochleation methods, cochleates and methods of use
US20050013854A1
